Role of Follistatin in Promoting Adipogenesis in Women
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
CONTEXT: Follistatin is a glycoprotein that binds and neutralizes biological activities of TGFbeta superfamily members including activin and myostatin. We previously identified by expression profiling that follistatin levels in white adipose tissue (WAT) were regulated by obesity. OBJECTIVE: The objective of the study was to elucidate the role of follistatin in human WAT and obesity. DESIGN: We measured secreted follistatin protein from WAT biopsies and fat cells in vitro. We also quantified follistatin mRNA expression in sc and visceral WAT and in WAT-fractionated cells and related it to obesity status, body region, and cellular origin. We investigated the effects of follistatin on adipocyte differentiation of progenitor cells in vitro. PARTICIPANTS: Women (n = 66) with a wide variation in body mass index were recruited by advertisement and from a clinic for weight-reduction therapy. RESULTS: WAT secreted follistatin in vitro. Follistatin mRNA levels in sc but not visceral WAT were decreased in obesity and restored to nonobese levels after weight reduction. Follistatin mRNA levels were high in the stroma-vascular fraction of WAT and low in adipocytes. Recombinant follistatin treatment promoted adipogenic differentiation of progenitor cells and neutralized the inhibitory action of myostatin on differentiation in vitro. Moreover, activin and myostatin signaling receptors were detected in WAT and adipocytes. CONCLUSION: Follistatin is a new adipokine important for adipogenesis. Down-regulated WAT expression of follistatin in obesity may counteract adiposity but could, by inhibiting adipogenesis, contribute to hypertrophic obesity (large fat cells) and insulin resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013
Dynamics of fat cell turnover in humans
Spalding, K. L., Arner, E., Westermark, P. O., Bernard, S., Buchholz, B. A., Bergmann, O., Blomqvist, L., Hoffstedt, J., Näslund, E., Britton, T., et al. (2008) · Nature · doi:10.1038/nature06902 · Cited by 2,357 · cited 1×
“WAT mass can increase through a combination of hypertrophic increase in size of preexisting adipocytes and de novo hyperplasia of adipocytes by differentiation from residential progenitor cells in the stroma-vascular portion of WAT (35).”
BackgroundSelf-citationRegulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
From Blood Monocytes to Adipose Tissue-Resident Macrophages
Curat, C. A., Miranville, A., Sengenès, C., Diehl, M., Tonus, C., Busse, R., & Bouloumié, A. (2004) · Diabetes · doi:10.2337/diabetes.53.5.1285 · Cited by 600
Gonzalez-Cadavid, N. F., Taylor, W. E., Yarasheski, K., Sinha-Hikim, I., Ma, K., Ezzat, S., Shen, R., Lalani, R., Asa, S., Mamita, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14938 · Cited by 571
Self-citationPrimary structure of the human follistatin precursor and its genomic organization
Shimasaki, S., Koga, M., Esch, F., Cooksey, K., Mercado, M., Koba, A., Ueno, N., Ying, S. Y., Ling, N., & Guillemin, R. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.12.4218 · Cited by 232 · cited 1×
“Only one isoform of follistatin, which most probably corresponds to the largest isoform FS315 was detected in WAT (32, 33).”
BackgroundSidis, Y., Mukherjee, A., Keutmann, H., Delbaere, A., Sadatsuki, M., & Schneyer, A. (2006) · Endocrinology · doi:10.1210/en.2006-0089 · Cited by 211
Insulin Resistance in Type 2 Diabetes - Role of the Adipokines
Arner, P. (2005) · Current Molecular Medicine · doi:10.2174/1566524053766022 · Cited by 201 · cited 1×
“to control energy homeostasis and metabolism (3).”
Self-citationEldar-Geva, T., Spitz, I. M., Groome, N. P., Margalioth, E. J., & Homburg, R. (2001) · Human Reproduction · doi:10.1093/humrep/16.12.2552 · Cited by 94 · cited 1×
“Importantly, human WAT follistatin is probably acting locally because circulating follistatin levels are not affected by obesity status (23).”
Background
Cited by
Diamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
Hansen, J., Brandt, C., Nielsen, A. R., Hojman, P., Whitham, M., Febbraio, M. A., Pedersen, B. K., & Plomgaard, P. (2011) · Endocrinology · doi:10.1210/en.2010-0868 · Cited by 200
Activin A Plays a Critical Role in Proliferation and Differentiation of Human Adipose Progenitors
Zaragosi, L.-E., Wdziekonski, B., Villageois, P., Keophiphath, M., Maumus, M., Tchkonia, T., Bourlier, V., Mohsen-Kanson, T., Ladoux, A., Elabd, C., et al. (2010) · Diabetes · doi:10.2337/db10-0013 · Cited by 184
Circulating follistatin is liver-derived and regulated by the glucagon-to-insulin ratio
Hansen, J. S., Rutti, S., Arous, C., Clemmesen, J. O., Secher, N. H., Drescher, A., Gonelle-Gispert, C., Halban, P. A., Pedersen, B. K., Weigert, C., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3668 · Cited by 125
Myostatin: more than just a regulator of muscle mass
Argilés, J. M., Orpí, M., Busquets, S., & López-Soriano, F. J. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.02.001 · Cited by 125
Metadata
- Authors
- Flanagan, J. N., Linder, K., Mejhert, N., Dungner, E., Wahlen, K., Decaunes, P., Rydén, M., Björklund, P., Arver, S., Bhasin, S., Bouloumie, A., Arner, P., & Dahlman, I.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-08-01
- Volume
- 94
- Issue
- 8
- Pages
- 3003-3009
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2171673792
- Cited by
- 64
- References
- 9
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.